Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes

References

• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013;6:289–296.
   PubMed Web of Science ®Google Scholar
• Villacampa G, Dienstmann R, Bosch F, et al. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and Meta-analysis. Ann Hematol. 2021;100(12):2969–2978.
   PubMed Web of Science ®Google Scholar
• Bašić-Kinda S, Radman I, Dujmović D, et al. R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. Ann Hematol. 2021;100(6):1517–1524.
   PubMed Web of Science ®Google Scholar
• Pejsa V, Prka Z, Lucijanic M, et al. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J. 2017;58(1):40–48.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• García-Suárez J, Bañas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136(2):276–285.
   PubMed Web of Science ®Google Scholar
• Matsuda S, Suzuki R, Takahashi T, et al. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. Int J Hematol. 2020;112(6):807–816.
   PubMed Web of Science ®Google Scholar
• Dunne RF, Loh KP, Williams GR, et al. Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers (Basel). 2019;11(12):1861.
   PubMed Web of Science ®Google Scholar
• Gallois C, Bourillon C, Auclin E, et al. Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: an AGEO prospective multicenter study. J Clin Oncol. 2020;38(15_suppl):4025–4025.
   Web of Science ®Google Scholar
• Daly LE, Ní Bhuachalla ÉB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia, Sarcopenia Muscle. 2018;9(2):315–325.
   PubMed Web of Science ®Google Scholar
• Park SE, Choi JH, Park JY, et al. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep. 2020;10(1):17683.
   PubMed Web of Science ®Google Scholar
• Iltar U, Sözel H, Sözel YK, et al. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2020;62:1–9.
   PubMed Web of Science ®Google Scholar
• Lucijanić M, Huzjan Korunic R, Ivić M, et al. Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkinʼs lymphoma patients. Wien Klin Wochenschr. 2021.
   Web of Science ®Google Scholar
• Lucijanic M, Huzjan Korunic R, Sedinic M, et al. More pronounced muscle loss during immunochemotherapy is associated with worse clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features. TCRM. 2021;17:1037–1044.
   Google Scholar
• Lanic H, Kraut-Tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma. 2014;55(4):817–823.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hara T, Shibata Y, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015;94(12):2043–2053.
   PubMed Web of Science ®Google Scholar
• Rier HN, Kharagjitsing H, van Rosmalen J, et al. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(7):1618–1626.
   PubMed Web of Science ®Google Scholar
• Go SI, Park MJ, Song HN, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7(5):567–576.
   PubMed Web of Science ®Google Scholar
• Lucijanić M, Huzjan Korunić R, Sedinić M, et al. Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type. Leuk Lymphoma. 2021;62:2535–2538..
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Huzjan Korunic R, Ivic M, et al. Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients. Hematol Oncol. 2021;39(4):575–579.
   PubMed Web of Science ®Google Scholar
• Landgren O, Andrén H, Nilsson B, et al. Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial? Ann Oncol. 2005;16(5):838–840.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, et al. Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. Ann Hematol. 2017;96(7):1155–1162.
   PubMed Web of Science ®Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25(3):669–674.
   PubMed Web of Science ®Google Scholar
• Scheich S, Enßle JC, Mücke VT, et al. Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation. PLoS One. 2019;14(11):e0225035.
   PubMed Web of Science ®Google Scholar
• Lucijanić M. Survival analysis in clinical practice: analyze your own data using an excel workbook. Croat Med J. 2016;57(1):77–79.
   PubMed Web of Science ®Google Scholar
• Lucijanić M. An update to the custom-made MS excel workbook performing the log-rank test with extended functionality and a new original COVID-19 training data set. Croat Med J. 2021;62(5):531–533.
   PubMed Web of Science ®Google Scholar
• Camus V, Lanic H, Kraut J, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93(1):9–18.
   PubMed Web of Science ®Google Scholar
• Besutti G, Massaro F, Bonelli E, et al. Prognostic impact of muscle quantity and quality and fat distribution in diffuse large B-cell lymphoma patients. Front Nutr. 2021;8:620696–620696.
   PubMed Web of Science ®Google Scholar
• Vázquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res. 2008;39(8):715–728.
   PubMed Web of Science ®Google Scholar
• Enerbäck S. Human brown adipose tissue. Cell Metab. 2010;11(4):248–252.
   PubMed Web of Science ®Google Scholar